Senseonics Holdings, Inc. Reaffirms Revenue Guidance for the First Half and Provides Revenue Guidance for the Full Year of 2024
June 21, 2024 at 09:05 pm
Share
Senseonics Holdings, Inc. reaffirmed revenue guidance for the first half and provided revenue guidance for the full year of 2024. For the six months, the company expects global net revenue to be $10 million, representing growth of approximately 21% compared to the first half of 2023.
For the full year, the company expects full year 2024 global net revenue to be in the range of $22 million to $24 million. The full year 2024 financial outlook assumes more than doubling the U.S. new patient starts and increasing the global installed base by approximately 50% in 2024 compared to 2023.
Senseonics Holdings, Inc. is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the diabetes community. Its glucose monitoring (CGM) systems, Eversense, Eversense XL, and Eversense E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every five minutes to a mobile app on the user's smartphone. Eversense consists of three primary components: a small sensor inserted subcutaneously under the skin by a healthcare provider; an external removable smart transmitter that receives, assesses and relays data from the sensor and provides vibratory alerts; and a mobile app that receives data from the transmitter and provides real-time glucose readings, alerts and other data the person's mobile device. Its CGM system continually and accurately measures a person's glucose levels for up to six months.
SENSEONICS HOLDINGS, INC. 
